Abrocitinib for eczema

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Apr 2020: Trial registered, NCT04345367
  2. 11 Jun 2020: Trial started, NCT04345367

The trials

NCT04345367: Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

State
Completed
Phase
Phase 3
People
727 taking part
Started
11 Jun 2020
Primary completion
13 Jul 2021
Arms
Abrocitinib 200 mg plus placebo injection
Results
Posted on the registry
  1. 14 Apr 2020: Trial registered
  2. 11 Jun 2020: Trial started
  3. 13 Jul 2021: Trial completed
  4. 8 Jul 2022: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Abrocitinib 200 mg, Cibinqo.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.